Abstract
目的探讨利妥昔单抗联合二线方案治疗复发难治性霍奇金淋巴瘤(HL)患者的疗效及安全性。方法7例复发难治性HL患者中2例接受R-GDP(E) [利妥昔单抗、吉西他滨、顺铂、地塞米松、(依托泊苷)]方案治疗,2例接受R-IGVP(利妥昔单抗、异环磷酰胺、吉西他滨、长春瑞滨、泼尼松)方案治疗,3例接受R-BEACOPP(利妥昔单抗、博来霉素、依托泊苷、多柔比星、环磷酰胺、长春新碱、甲基苄肼、泼尼松)方案治疗。观察患者治疗过程中及其后的不良反应和疗效。结果7例患者中男3例,女4例,发病时中位年龄21(12~36)岁;结节性淋巴细胞为主型HL(NLPHL) 1例,经典型HL 6例(包括4例结节硬化型,1例淋巴细胞为主型和1例混合细胞型)。中位疗程数为4(1~4)个,中位随访时间为29(24~58)个月。7例患者中4例达完全缓解,2例达疾病稳定,1例死亡。2年总生存率为85.7%。不良反应均可耐受,以骨髓抑制为主。5例患者化疗后行外周血自体造血干细胞移植治疗。结论利妥昔单抗联合二线方案治疗复发难治性HL患者安全、有效。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.